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Abstract
Women at high risk of preterm birth (either a previous spontaneous preterm birth 
and/or sonographic short cervix) with a singleton gestation should be offered daily 
vaginal progesterone or weekly 17- OHPC treatment to prevent preterm birth. Benefit 
is most significant in those with prior history of preterm birth and a short cervix. For 
women with a previous spontaneous preterm birth and a cervix ≥30 mm the effective-
ness of progesterone is uncertain. In asymptomatic women with no prior history of 
previous preterm birth, no mid- trimester loss, or no short cervical length, progester-
one therapy is not recommended for the prevention of preterm birth. For those with 
unselected multiple pregnancies, progesterone therapy is not recommended for the 
prevention of preterm birth. Daily vaginal progesterone or weekly 17- OHPC treat-
ment can be used for the prevention of preterm birth. The preparation used should be 
decided by the woman and her clinician. There is no evidence of neurological or de-
velopmental benefit or harm in babies whose mothers use progestogens for preterm 
birth prevention antenatally.
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1  |  INTRODUC TION
Endogenous progesterone is essential for the maintenance of preg-
nancy, and local decline in progesterone activity is thought to have a 
role in labor induction. Therefore, progestogens have been increas-
ingly used in women at high risk of preterm birth as they are believed 
to counter this functional decline and provide anti- inflammatory ef-
fects. Several randomized controlled trials (RCTs) and meta- analyses 
have been undertaken to help provide an evidence- based approach 
to prevent preterm birth and determine the optimal regimes and 
populations to target.
Types of progestogens:
1. Natural progesterone, similar to that produced by the body 
and commonly administered as a vaginal gel or pessary
2. Semisynthetic progestogens, which have a different chemical 
structure and include 17- hydroxyprogesterone caproate (17- 
OHPC), given as a weekly intramuscular injection.
2  |  A SYMPTOMATIC WOMEN WITH A 
SINGLETON GESTATION AT HIGH RISK OF 
PRETERM BIRTH
The EPPPIC meta- analysis included individual patient data from ran-
domized trials of progestogens to prevent preterm birth, including 
31 trials and 11 644 participants.1 It demonstrated that both vaginal 
progesterone and 17- OHPC reduced the risk of preterm birth before 
34 weeks for a high- risk population with singleton gestations. In ad-
dition, a benefit was seen among included participants who were 
only eligible for the original trials due to short cervical length (de-
fined by different thresholds in different trials) or history of preterm 
birth (vaginal progesterone: 9 trials, 3769 women; relative risk [RR] 
0.78, 95% CI 0.68– 0.90; 17- OHPC: 5 trials, 3053 women; RR 0.83, 
95% CI 0.68– 1.01).
Recommendation: Women at high risk of preterm birth (either a 
previous spontaneous preterm birth and/or sonographic short cervix) 
with a singleton gestation should be offered daily vaginal progester-
one or weekly 17- OHPC treatment to prevent preterm birth. Whether 
progesterone is effective in women with previous spontaneous preterm 
birth and a normal length cervix (>30 mm at midtrimester ultrasound) is 
uncertain.
3  |  A SYMPTOMATIC WOMEN WITH A 
SINGLETON GESTATION WITHOUT A PRIOR 
HISTORY OF PRETERM BIRTH OR SHORT 
CERVIC AL LENGTH
In the EPPPIC meta- analysis, the effect of progestogens on pre-
term birth reduction did not statistically differ based on the his-
tory of preterm birth or the presence of a short cervix. However, 
few women enrolled in any of the included trials that did not have 
either of these risk factors. As such, it remains uncertain whether 
and to what extent progestogens will or will not benefit this 
population.
Recommendation: In asymptomatic women with no prior history of 
previous preterm birth, no mid- trimester loss, or no short cervical length, 
progesterone therapy is not recommended for the prevention of preterm 
birth.
4  |  A SYMPTOMATIC WOMEN WITH A 
MULTIPLE PREGNANCY
The EPPPIC meta- analysis shows that progestogen administration 
does not reduce preterm birth before 34 weeks in women with un-
selected multiple pregnancies (16 trials; vaginal progesterone: RR 
1.01, 95% CI 0.84– 1.20; 17- OHPC: RR 1.04, 95% CI 0.92– 1.18).1 The 
majority of women included in the meta- analysis had no other risk 
factors for preterm birth. This is consistent with the 2019 Cochrane 
review, which included 16 trials and 4548 women.2 A recent addi-
tional study came to the same conclusion for unselected multiple 
pregnancies.3
Recommendation: For women with unselected multiple pregnancies, 
progesterone therapy is not recommended for the prevention of preterm 
birth. For women with multiple pregnancies and a risk factor such as 
previous preterm birth, it is unknown whether progesterone therapy is 
effective.
5  |  OTHER ISSUES
5.1  |  Type of progestogen
In the EPPPIC meta- analysis, there were only two trials that pro-
vided direct data comparing vaginal progesterone and 17- OHPC, 
and these showed no statistical difference between the two 
types of progestogen (preterm birth <34 weeks RR 1.18, 95% CI 
0.69– 2.03).1
Recommendation: Daily vaginal progesterone or weekly 17- OHPC 
treatment can be used for the prevention of preterm birth. The prepara-
tion used should be decided by the woman and her clinician.
5.2  |  Long- term effects of progestogens
Only two studies have examined the long- term effects of pro-
gestogens in those with singleton gestations.4,5 The follow- up 
study to the Meis et al. 2003 trial of 17- OHPC showed no dif-
ference between 17- OHPC and placebo groups in any of the de-
velopmental domains of children assessed at approximately two 
years.4 A childhood developmental assessment was one of the 
three primary outcomes in the OPPTIMUM study, which showed 
no difference in cognitive composite score between the active 
and the placebo groups.5 A recent systematic review comprising a 
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multitude of developmental measurements with a broad age range 
at assessment did not find evidence of benefit or harm in offspring 
prenatally exposed to progesterone treatment for the prevention 
of preterm birth (5 trials, 4222 measurements of children between 
6 months and 8 years).6
Recommendation: There is no evidence of neurological or develop-
mental benefit or harm in babies whose mothers use progestogens for 
preterm birth prevention antenatally.
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